CalciMedica, Inc.
CALCNasdaq
$0.74
↑ +6.0%Jul 17 close · end-of-day
Price
1Y↓ -66.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$12.0M
Enterprise Value
$3.8M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-176.3%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$19.5M
Free Cash Flow (TTM)
-$21.2M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
1770.1%
ROIC
—
Debt / Equity
—
Net Cash
$8.2M
Return 1Y
-70.8%
Company profile
CalciMedica, Inc. focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials. GB-401, an implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma.
- CEO
- Frédéric Guerard
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- California
- Website
- calcimedica.com
Management & directors
- Hebbar SudarshanChief Medical Officer
- Leheny A. RachelCHIEF EXECUTIVE OFFICER
- Roberts Eric WCHIEF BUSINESS OFFICER
- Stauderman Kenneth A.Chief Scientific Officer
- Bardin StephenChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
CALC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS$0.30↓ -183.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$29.8M | -$35.9M | -$14.2M | -$38.1M | -$24.2M | -$23.1M |
| Net income | -$27.5M | -$35.8M | -$7.8M | -$34.4M | -$13.7M | -$29.6M |
| Diluted EPS | — | -$1.69 | -$111.16 | -$7.66 | -$1.22 | -$1.97 |
| Operating cash flow | -$32.1M | -$31.5M | -$11.8M | -$25.7M | -$21.1M | -$21.2M |
| Free cash flow | -$33.1M | -$32.0M | -$11.8M | -$25.8M | -$21.2M | -$21.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$6.5M | -$5.7M | -$6.2M | -$6.5M | -$6.6M | -$5.6M | -$4.4M | -$5.6M |
| Net income | -$4.0M | -$5.6M | -$4.3M | -$5.0M | -$6.0M | -$7.8M | -$10.8M | $5.0M |
| Diluted EPS | -$0.36 | -$0.50 | -$0.37 | -$0.36 | -$0.40 | -$0.52 | -$0.69 | $0.30 |
| Operating cash flow | -$6.8M | -$4.7M | -$5.0M | -$4.9M | -$6.7M | -$4.8M | -$4.9M | -$4.9M |
| Free cash flow | -$6.8M | -$4.7M | -$5.0M | -$4.9M | -$6.7M | -$4.8M | -$4.9M | -$4.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 24, 2026
Mar 3, 2026
Jan 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-25 | WILSON ROBERT N | Award | 1,182,621 | $0.80 | $949,999.45 | filing |
| 2026-06-25 | MIDDLETON FRED A | Buy | 248,972 | $0.80 | $199,999.21 | filing |
| 2026-06-25 | Roberts Eric W· CHIEF BUSINESS OFFICER | Award | 186,729 | $0.80 | $149,999.41 | filing |
| 2026-06-25 | Leheny A. Rachel· CHIEF EXECUTIVE OFFICER | Award | 186,729 | $0.80 | $149,999.41 | filing |
| 2026-06-25 | Hebbar Sudarshan· Chief Medical Officer | Award | 124,486 | $0.80 | $99,999.60 | filing |
| 2025-09-18 | Roberts Eric W· CHIEF BUSINESS OFFICER | Buy | 2,500 | $3.07 | $7,675.00 | filing |
| 2025-09-15 | Roberts Eric W· CHIEF BUSINESS OFFICER | Buy | 3,400 | $2.68 | $9,104.86 | filing |
| 2025-09-12 | Roberts Eric W· CHIEF BUSINESS OFFICER | Buy | 5,000 | $3.12 | $15,600.00 | filing |
| 2025-09-09 | Roberts Eric W· CHIEF BUSINESS OFFICER | Buy | 2,343 | $3.15 | $7,377.64 | filing |
| 2025-08-29 | Roberts Eric W· CHIEF BUSINESS OFFICER | Buy | 800 | $2.74 | $2,192.00 | filing |
| 2025-08-28 | Roberts Eric W· CHIEF BUSINESS OFFICER | Buy | 9,200 | $2.86 | $26,339.60 | filing |
| 2025-08-21 | Roberts Eric W· CHIEF BUSINESS OFFICER | Buy | 3,508 | $2.79 | $9,797.14 | filing |
| 2025-08-20 | Roberts Eric W· CHIEF BUSINESS OFFICER | Option exercise | 15,000 | $1.53 | $22,950.00 | filing |
| 2025-08-20 | Roberts Eric W· CHIEF BUSINESS OFFICER | Buy | 2,000 | $2.72 | $5,440.00 | filing |
| 2025-08-19 | Hebbar Sudarshan· Chief Medical Officer | Buy | 9,563 | $2.82 | $26,961.92 | filing |
| 2025-08-19 | Roberts Eric W· CHIEF BUSINESS OFFICER | Buy | 1,000 | $2.79 | $2,790.00 | filing |
| 2025-08-15 | Roberts Eric W· CHIEF BUSINESS OFFICER | Buy | 5,076 | $2.90 | $14,708.73 | filing |
| 2025-08-15 | Hebbar Sudarshan· Chief Medical Officer | Buy | 4,392 | $2.79 | $12,266.86 | filing |
| 2025-08-14 | Hebbar Sudarshan· Chief Medical Officer | Buy | 1,584 | $2.59 | $4,094.64 | filing |
| 2025-07-28 | Stauderman Kenneth A.· Chief Scientific Officer | Buy | 1,000 | $3.96 | $3,960.00 | filing |
| 2025-07-25 | Stauderman Kenneth A.· Chief Scientific Officer | Sale | 1,000 | $3.65 | $3,650.00 | filing |
| 2025-07-22 | Roberts Eric W· CHIEF BUSINESS OFFICER | Buy | 1,500 | $3.78 | $5,662.50 | filing |
| 2025-07-21 | Roberts Eric W· CHIEF BUSINESS OFFICER | Buy | 1,500 | $3.37 | $5,055.00 | filing |
| 2025-07-21 | Leheny A. Rachel· CHIEF EXECUTIVE OFFICER | Buy | 1,000 | $3.40 | $3,400.00 | filing |
| 2025-07-18 | WILSON ROBERT N | Buy | 4,500 | $2.87 | $12,915.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.